GLP1R and metabolic dysfunction-associated steatohepatitis: This has led to the hypothesis that inhibiting DPP-4 could potentially improve the histological characteristics of MASLD and MASH (non-alcoholic steatohepatitis) by preserving GLP-1’s beneficial actions [158].